loncastuximab tesirine

loncastuximab tesirine ADC Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma LAUSANNE, Switzerland–(BUSINESS […]

» Read more
1 2 3 36